JENNIFER RUSSUM: Open Payments
NPI 1376951921 · CLINTON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,399 in 71 payments from 16 companies in 2025. Trend: 2023 $363 · 2024 $841 · 2025 $1,399
Food & beverage: $1,399
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 15 | $291 |
| ABBVIE INC. | 17 | $260 |
| Novo Nordisk Inc | 8 | $143 |
| Kowa Pharmaceuticals America, Inc. | 2 | $120 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $115 |
| Lilly USA, LLC | 3 | $81 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $76 |
| Amgen Inc. | 3 | $71 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Stryker Corporation | 1 | $49 |
Products named: FARXIGA, VRAYLAR, ZORYVE, CAPLYTA, Ozempic, XIFAXAN, MOUNJARO, UBRELVY.
Industry payments across MS — which companies pay providers there.
